Figure S2 from <i>ercc1</i> Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a <i>tp53</i> Context-Specific Manner

S2.(a) µCT-based monitoring of tumor response in K and KE mice prior to and after cisplatin treatment (left). Quantification of tumor volume in K and KE mice prior to and after cisplatin treatment (right). P values were calculated using two-tailed t-test. (b) Representative immunostaining of Pt-(GpG) adducts in tumor lung sections of KP and KPE mice after single cisplatin treatment (left). Quantification of Pt-(GpG) adduct staining in of KP (n = 3) and KPE mice (n = 4) after single cisplatin treatment (right). P values were calculated using two-tailed t-test. (c) Survival of chemo-naive vs. cisplatin-treated KrasLSL.G12D/wt (K) mice (top left), chemo-naive vs. cisplatin-treated KrasLSL.G12D/wt;Ercc1fl/fl (KE) mice (top right) and comparison of cisplatin-treated KrasLSL.G12D/wt (K) and cisplatin-treated KrasLSL.G12D/wt;Ercc1fl/fl (KE) mice (bottom). P values were calculated using log-rank test.